Becton, Dickinson's stock momentum is improving, but geopolitical risks and global headwinds warrant caution. Click here to ...

Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.

BDX currently has a forward P/E ratio of 16.38, while MMSI has a forward P/E of 27.40. We also note that BDX has a PEG ratio of 1.71. This popular figure is similar to the widely-used P/E ratio, but ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Fund” fourth quarter 2024 investor letter. A copy ...

BD. (BDX), a global medical technology company, and Biosero, a developer of laboratory automation solutions, Thursday announced that ...

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $237.38 which represents a slight increase of $1.08 or 0.46% from the prior close of $236.3. The stock opened at $236.51 and ...

Gateway Investment Advisers LLC reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by ...

Becton, Dickinson and Company and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, announced a ...

Below is Validea's guru fundamental report for BECTON DICKINSON AND CO (BDX). Of the 22 guru strategies we follow, BDX rates highest using our P/E/Growth Investor model based on the published ...

The new versions of BD flow cytometer instrument software compatible with Biosero automation software for the BD FACSymphony A1™ Cell Analyzer, BD FACSymphony™ A5 SE Cell Anal ...

In a recent transaction, Shan David, Executive Vice President and Chief ISC Officer at Becton Dickinson & Co (NYSE:BDX), sold ...